$10.52
+0.30 (+2.94%)
Open$10.73
Previous Close$10.22
Day High$10.74
Day Low$10.50
52W High$12.10
52W Low$4.52
Volume—
Avg Volume5.4K
Market Cap90.37M
P/E Ratio114.77
EPS$0.08
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-59.4% upside
Current
$10.52
$10.52
Target
$4.27
$4.27
$3.74
$4.27 avg
$6.64
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 27.76M | 24.31M | 25.83M |
| Net Income | -1,044,170 | -823,045 | 1.23M |
| Profit Margin | -3.8% | -3.6% | 4.8% |
| EBITDA | 2.13M | 1.77M | 1.46M |
| Free Cash Flow | — | — | 1.13M |
| Rev Growth | +14.2% | +14.2% | +0.8% |
| Debt/Equity | 0.34 | 0.34 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |